• news.cision.com/
  • SyntheticMR AB/
  • SyntheticMR announces estimated net sales of SEK 12m. (21.2) for quarter 2 of 2024 depending on organizational changes in USA. The net sales target for 2024 is therefore not expected to be achieved
English

SyntheticMR announces estimated net sales of SEK 12m. (21.2) for quarter 2 of 2024 depending on organizational changes in USA. The net sales target for 2024 is therefore not expected to be achieved

Report this content

The costs for the second quarter are expected to be on a par with the same period last year, which therefore also applies to the entire first half of 2024. This outcome is the result of good cost control and efficiency improvements in operations globally. All figures are preliminary and unaudited. The full interim report for the second quarter will be published on August 27, 2024, as previously announced.

"We know from experience that our business sometimes has large fluctuations over the quarters. After four straight quarters of record sales, we have now been negatively affected by unforeseen events in the organization. This has led to a number of sales processes being hampered. The situation is isolated to the subsidiary in the USA. Other priority regions continue to develop well. Positive in this context is also that the response from the market in North America as well as globally for our offer is undiminished strong," says Ulrik Harrysson, CEO, SyntheticMR.




 

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-07-2024 21:34 CET.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com 

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.

Subscribe